Primary hyperaldosteronism medical therapy: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
The optimal therapy for primary hyperladosteronism depends on the etiology of hyperaldosteronism. | |||
==Medical Therapy== | ==Medical Therapy== | ||
The | Medical therapy is indicated for bilateral adrenal hyperplasia and all ambiguous causes of primary hyperaldosteronism. The following agents may be used to medical management of primary hyperaldosteronism: | ||
===Mineralocorticoid receptor antagonists=== | |||
*Spironolactone | |||
*Potassium canrenoate | |||
*Eplerenone | |||
The first two have affinity for androgen and progesterone receptors, causing side effects such as, gynecomastia (6.9% at dose < 50 mg / day and 52% at dose > 150 mg / day),[108] sexual dysfunction, and menstrual irregularities. Spironolacone is used at a starting dose of 12.5 – 25 mg twice daily and increased gradually to a maximum of 400 mg per day. Eplerenone is a selective mineralcorticoid receptor antagonist without antiandrogen and progesterone agonist activity. It is 60% as potent as spironolactone and should be administered twice daily because of its short half life. It has been shown to be as effective as spironolactone. | |||
Potassium-sparing diuretics — amiloride, triamterene. Potassium-sparing diuretics, such as triamterene or amiloride, have been used, although they are usually not as effective as spironolactone | |||
Other anti-hypertensives — calcium channel blockers, ACE inhibitors, angiotensin receptor blockers, and low doses of thiadzides diuretics. | |||
{{reflist|2}} | {{reflist|2}} | ||
{{WH}} | {{WH}} | ||
Revision as of 15:08, 10 July 2017
Template:Conn syndrome Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
The optimal therapy for primary hyperladosteronism depends on the etiology of hyperaldosteronism.
Medical Therapy
Medical therapy is indicated for bilateral adrenal hyperplasia and all ambiguous causes of primary hyperaldosteronism. The following agents may be used to medical management of primary hyperaldosteronism:
Mineralocorticoid receptor antagonists
- Spironolactone
- Potassium canrenoate
- Eplerenone
The first two have affinity for androgen and progesterone receptors, causing side effects such as, gynecomastia (6.9% at dose < 50 mg / day and 52% at dose > 150 mg / day),[108] sexual dysfunction, and menstrual irregularities. Spironolacone is used at a starting dose of 12.5 – 25 mg twice daily and increased gradually to a maximum of 400 mg per day. Eplerenone is a selective mineralcorticoid receptor antagonist without antiandrogen and progesterone agonist activity. It is 60% as potent as spironolactone and should be administered twice daily because of its short half life. It has been shown to be as effective as spironolactone. Potassium-sparing diuretics — amiloride, triamterene. Potassium-sparing diuretics, such as triamterene or amiloride, have been used, although they are usually not as effective as spironolactone Other anti-hypertensives — calcium channel blockers, ACE inhibitors, angiotensin receptor blockers, and low doses of thiadzides diuretics.